Acta Pharmaceutica Sinica B · 2020 · 38 citations · 49 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular PharmacologyLigand BindingLigand-based DesignMolecular DockingPotency OptimizationProtein-ligand DockingBinding Pocket GeometryDocking-based Drug DesignMechanism-based Drug DesignMesenchymal TransitionMolecular Similarity DesignProperty-based Drug DesignStructure-based Ligand DesignTherapeutic Target Identification
Histone lysine specific demethylase 1 (LSD1) has become a potential therapeutic target for the treatment of cancer. Discovery and develop novel and potent LSD1 inhibitors is a challenge, although several of them have already entered into clinical trials. Herein, for the first time, we reported the discovery of a series of 5-cyano-6-phenylpyrimidine derivatives as LSD1 inhibitors using flavin adenine dinucleotide (FAD) similarity-based designing strategy, of which compound 14q was finally identified to repress LSD1 with IC50 = 183 nmol/L. Docking analysis suggested that compound 14q fitted well into the FAD-binding pocket. Further mechanism studies showed that compound 14q may inhibit LSD1 activity competitively by occupying the FAD binding sites of LSD1 and inhibit cell migration and invasion by reversing epithelial to mesenchymal transition (EMT). Overall, these findings showed that compound 14q is a suitable candidate for further development of novel FAD similarity-based LSD1 inhibitors.
49
The Determination of Enzyme Dissociation Constants
Hans Lineweaver, Dean Burk · Journal of the American Chemical Society · 1934 · 12.1K citations
Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1
Yujiang Geno Shi, Yujiang Geno Shi, Fei Lan et al. · Cell · 2004 · 4K citations · Full text
LSD1 Is a Subunit of the NuRD Complex and Targets the Metastasis Programs in Breast Cancer
Yan Wang, Hua Zhang, Yupeng Chen et al. · Cell · 2009 · 683 citations